Eris Lifesciences Ltd (NSE: ERIS) and Marksans Pharma Ltd. (NSE: MARKSANS) are both listed in the Pharmaceuticals industry. Eris Lifesciences has a market capitalisation of ₹16,096 Cr and Marksans Pharma ₹14,152 Cr, as of 9 Nov 2026. Their P/E ratios are 25.6 and 33.9 respectively. Return on equity is 18.07% for Eris Lifesciences and 25.45% for Marksans Pharma. Over one year, Eris Lifesciences's share price is down 21.1% and Marksans Pharma's is up 62.3%.
| Metric | Eris Lifesciences | Marksans Pharma |
|---|---|---|
| NSE Symbol | ERIS | MARKSANS |
| BSE Code | 540596 | 524404 |
| Share Price | ₹1,255.50 | ₹309.00 |
| Market Cap | ₹16,096 Cr | ₹14,152 Cr |
| P/E Ratio | 25.6 | 33.9 |
| Return on Equity | 18.07% | 25.45% |
| Return on Assets | 7.30% | 8.85% |
| Dividend Yield | 1.24% | 0.29% |
| Beta (1Y) | 0.07 | 0.7 |
| 1-Year Price Change | -21.1% | +62.3% |
| 3-Month Price Change | -9.9% | +13.8% |
| 52-Week Range | ₹1,069.00 – ₹1,740.00 | ₹155.00 – ₹350.95 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹892 Cr | ₹940 Cr |
| Quarterly Net Profit | ₹187 Cr | ₹144 Cr |
| Net Margin | 21.0% | 15.3% |
| EPS (Basic, Quarter) | ₹13.26 | ₹3.12 |
| Results Basis | consolidated | consolidated |
| Headquarters | Ahmedabad, Gujarat | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitor…
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeuti…
Eris Lifesciences has a market capitalisation of ₹16,096 Cr, against ₹14,152 Cr for Marksans Pharma as of 9 Nov 2026, about 1.1 times the size by market cap.
Eris Lifesciences has a P/E of 25.6 and Marksans Pharma a P/E of 33.9 as of 9 Nov 2026.
Eris Lifesciences has a return on equity of 18.07% and Marksans Pharma 25.45%.
Eris Lifesciences's share price is down 21.1% over one year and Marksans Pharma's is up 62.3%.
Eris Lifesciences reported revenue of ₹892 Cr and net profit of ₹187 Cr for Q2 FY27. Marksans Pharma reported revenue of ₹940 Cr and net profit of ₹144 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.